Neoadjuvant Study of DV Plus Toripalimab in Combination or Sequence With Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Conditions: Breast Cancer Interventions: Drug: Disitamab Vedotin Injection （18 weeks）; Drug: Toripalimab （18weeks）; Drug: Carboplatin; Drug: Disitamab Vedotin Injection （12 weeks）; Drug: Sequential Epirubicin; Drug: Sequential CTX; Drug: Toripalimab （12weeks） Sponsors: RemeGen Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials